Johnson & Johnson Stock News

Johnson & Johnson is halting production on their notable one-dose COVID-19 vaccine

Johnson & Johnson stopped production of its single-shot COVID-19 vaccine at the only plant making usable doses late last year, according to a report Tuesday.

Johnson & Johnson have temporarily shut down the only plant making usable batches of its COVID-19 vaccine, a New York Times report says.

The only Johnson & Johnson facility making usable batches of the company''s Covid vaccine has temporarily halted its production, The New York Times reported.

Johnson & Johnson has quietly paused production of its Covid vaccine, according to a media report US multinational Johnson & Johnson suspended production of its Covid-19 vaccine late last year amid a massive push by the federal government and health officials to promote getting inoculated, The New York Times reported on Tuesday, citing sources familiar with the situation. The pause in production is reportedly temporary, but the one plant producing the vaccine in the Dutch city of Leiden has apparently shifted its focus to producing a potentially more profitable vaccine for an unrelated virus. Its unclear if the production pause has affected the availability of the single-jab Covid vaccine, as the company has a stockpile of doses. However, one person familiar with the situation says the suspension could mean a reduction in output of a few hundred million doses. The plant is expected to produce more after a few months break. Other facilities are awaiting regulatory approval or to actually be up and running to produce the Johnson & Johnson vaccine, according to the NYT report.

Johnson & Johnson reportedly shut down the only plant making usable batches of its COVID-19 vaccine even though many poor and developing nations are relying on the shots to immunize their populations. The factory in the Dutch city of Leiden has shifted toward the production of more profitable vaccines that …

Johnson & Johnson temporarily halted production of its COVID-19 vaccine in The Netherlands, the only manufacturing hub making usable doses for the pharmaceutical company, according to a New York Times report on Tuesday.The company stopped…

BALTIMORE , Feb. 8, 2022 /PRNewswire-PRWeb/ -- VerImmune Inc. (VerImmune), a biotechnology company developing a new therapeutic modality that redirects the body''s pre-existing immunity toward cancer, announced that the company has entered into a Research Collaboration with Janssen Research & Development, LLC ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation. Verimmune is also a resident of JLABS @ Washington, DC ., part of Johnson & Johnson Innovation''s global network of life science incubators and plans to set up its research and development laboratories in this new cutting edge site located at the heart of the BioHealth Capital Region (BHCR) cluster which consists … Full story available on Benzinga.com

Halt is reported to be temporary

Johnson & Johnson late last year quietly shut down the only plant making usable batches of its COVID-19 vaccine, the New York Times reported, citing people familiar with the decision. The halt is temporary, with the Leiden plant expected to start making the vaccine again after a few months, the NYT report said. The paper added it was not clear whether the pause has had an impact on vaccine supplies yet, thanks to stockpiles. The company did not immediately respond to a Reuters request for comment. The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus, according to the report. The drugmaker last month forecast as much as $3.5 billion in sales of its COVID-19 vaccine in 2022, a 46% jump, having fared poorly compared to rivals. J&J expects COVID vaccine sales to jump as much as 46% in 2022 The company reported sales of $2.39 billion for the COVID shot in 2021, missing its own target of $2.5 billion, in a year marked by manufacturing stumbles, safety concerns and uneven demand for a vaccine once touted as a promising tool for inoculating populations in hard-to-reach areas.

Johnson & Johnson late last year shut down production of its COVID-19 vaccine at its plant in Leiden, Netherlands, its only facility in the world where usable batches are made.

Johnson & Johnson has halted the production of its COVID-19 vaccine at its plant in the Dutch city of Leiden in late 2021, according to a report published by the New York Times on Tuesday. While

The European Union has delivered 1,936,050 doses of Johnson & Johnson''s COVID-19 vaccine to Nigeria. The post Nigeria receives almost 2 million doses of J&J COVID vaccine from EU countries appeared first on Nairametrics .

AKOR SYLVESTER-Abuja Efforts to vaccinate all Nigerians against COVID-19 pandemic received a boost yesterday, as the European Union (EU) handed over 2 million doses of Johnson and Johnson COVID-19 vaccine to Nigeria for use in the country.. Receiving the vaccine unbehalf of the federal government in Abuja Monday, the Executive Director of the National Primary [] The post COVID-19: Nigeria gets 2m doses of Johnson & Johnson vaccine from EU appeared first on Champion Newspapers LTD .